Analysts think ARWR stock price could increase by 140%
Mar 07, 2025, 12:25 PM
-39.59%
What does ARWR do
Arrowhead Pharmaceuticals, based in Pasadena, California, develops RNA-based therapies targeting intractable diseases, employing 525 staff and featuring 14 clinical-stage investigational medicines across various therapeutic areas. Their TRiMTM platform enables tissue-specific delivery through RNA interference mechanisms.
16 analysts think ARWR stock price will increase by 139.56%. The current median analyst target is $42.33 compared to a current stock price of $17.67. The lowest analysts target is $21.21 and the highest analyst target is $84.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
